RapidAI Acquires EndoVantage

RapidAI Acquires Comprehensive Aneurysm Management Innovator and Expands Scope to Include Aneurysm, Extending Its Leadership in Cerebrovascular Imaging

MENLO PARK, Calif.–(BUSINESS WIRE)–#Rapid–RapidAI, the worldwide leader in advanced imaging for stroke, today announced the acquisition of EndoVantage, developer of the Find, Track and Treat™ comprehensive cerebral aneurysm management platform. A major neurological condition, it is estimated that 1 in 50 people in the U.S. has an unruptured cerebral aneurysm, with one rupturing and resulting in a brain hemorrhage every 18 minutes. With this news, RapidAI continues to expand its scope, from ischemic stroke to hemorrhagic stroke and now aneurysm.

In 2019, RapidAI introduced Rapid ICH, the next step in AI-powered imaging technology for hemorrhages. Now with the acquisition of EndoVantage, the company will also add a concentration on aneurysm. Started at Mayo Clinic and Arizona State University, EndoVantage has developed a powerful award-winning computational platform that provides comprehensive cerebral aneurysm management, automating the entire workflow from initial assessment, growth monitoring, to treatment planning. It utilizes CTA and MRA scans to deliver results that help physicians find and track aneurysm progression, and leverages data from 3D rotational angiograms to deliver detailed 3D models of a patient’s vasculature and allow presurgical planning for the repair of the aneurysm.

“By adding the incredible technology developed by EndoVantage to the Rapid platform, we strengthen our position as the global leader in cerebrovascular imaging,” said Don Listwin, CEO of RapidAI. “We can offer hospitals a complete portfolio of products—encompassing ischemic stroke, hemorrhagic stroke, and aneurysm—providing an end-to-end solution that will drive better patient outcomes across the spectrum of cerebrovascular disorders.”

“We are very excited to join the Rapid platform of technology. EndoVantage covers the spectrum of cerebral aneurysm care from diagnosis through treatment, which helps physicians decide how best to treat their patients,” said Brian Chong MD, cofounder, EndoVantage. “Each patient’s aneurysm is unique, like the patient. Our technology augments a physician’s clinical acumen and experience helping them determine the best plan for each patient.”

The complete Rapid® platform currently includes:

  • Rapid ICH: automatically triages non-contrast CT scans to quickly identify brain hemorrhages with a sensitivity of 95% and specificity 94%*
  • Rapid ASPECTS**: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury
  • Rapid CTA: automatically assesses regions of reduced blood flow to identify, locate, and alert stroke teams to the presence of large vessel occlusions (LVOs)**.
  • Rapid CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time
  • Rapid MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival
  • Rapid Mobile App: securely view Rapid results from multiple sites with customizable notifications on mobile devices

*When instances of hemorrhagic transformation type HI 1 are not included.

**Rapid ASPECTS and LVO detection and localization are not commercially available in the U.S.

About RapidAI

RapidAI is the worldwide leader in advanced imaging for stroke. Installed in over 1,500 hospitals in more than 50 countries, the Rapid imaging platform, powered by artificial intelligence, includes Rapid CTP, Rapid MRI, Rapid CTA, Rapid ICH, and Rapid ASPECTS*. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke patients using clinically proven, data-driven technology. With our validated, trusted platform, developed by stroke experts, clinicians worldwide are improving patient care and outcomes every day. The Rapid platform has been shown to aid in patient selection in both early and late-window clinical stroke trials. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, the results of these trials led to new American Heart Association and American Stroke Association treatment guidelines and have dramatically altered the management of acute stroke around the world. For more information, visit RapidAI.com.

Contacts

Peter Evers

Natron Communications for RapidAI

(415) 524-8899
pr@RapidAI.com